Maze Therapeutics (MAZE) – Analysts’ Recent Ratings Changes

Maze Therapeutics (NASDAQ: MAZE) has recently received a number of price target changes and ratings updates:

• 3/31/2026 – Maze Therapeutics had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an “overweight” rating on the stock.
• 3/28/2026 – Maze Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/25/2026 – Maze Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
• 3/25/2026 – Maze Therapeutics had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Maze Therapeutics is now covered by Truist Financial Corporation. They set a “buy” rating and a $68.00 price target on the stock.
• 3/17/2026 – Maze Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/16/2026 – Maze Therapeutics had its price target raised by Wedbush from $43.00 to $58.00. They now have an “outperform” rating on the stock.
• 3/11/2026 – Maze Therapeutics was upgraded by Mizuho to “strong-buy”.
• 3/10/2026 – Maze Therapeutics is now covered by Mizuho. They set an “outperform” rating and a $97.00 price target on the stock.
• 3/9/2026 – Maze Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
• 3/4/2026 – Maze Therapeutics had its price target raised by Guggenheim from $46.00 to $58.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at $596,908.60. This trade represents a 27.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $44.27, for a total value of $332,025.00. Following the transaction, the insider owned 10,503 shares of the company’s stock, valued at approximately $464,967.81. The trade was a 41.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 95,000 shares of company stock worth $4,245,625 over the last 90 days.

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.